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ABSTRACT
Objective: This study was designed to evaluate the potential antioxidant effect of vitamin D3 supplementation in chronic asthma patients.
Methods: A total of 44 candidate patients were diagnosed with asthma allocated as Group 1 includes 20 patients assigned to receive conventional 
therapy for asthma and Group 2 includes 24 patients assigned to receive conventional therapy for asthma plus 2000 IU vitamin D3 tablet for 3-month 
period. Furthermore, 30 apparently healthy subjects were included in the study as a control group. Pulmonary function test, serum 25-hydroxy 
vitamin D levels, serum extracellular superoxide dismutase (SOD3) levels were measured before and after 3 months therapy.
Results: The mean forced expiratory volume in 1 second (FEV1) both the measured and the percentage of predicted value showed a highly significant 
increase after 3 months treatment compared to pre-treatment value in both study groups (p<0.01). When compared to pre-treatment value, there 
was no significant increase in forced expiratory volume in one second to forced vital capacity ratio (FEV1/FVC) in Group 1 (p>0.05), nevertheless, 
Group 2 showed highly significant increase after 3 months (p<0.01). Approximately, 90-96% of adult asthmatic patients revealed vitamin D deficiency 
(<20 ng/ml). Post-treatment with adjuvant vitamin D3 therapy, 25% of patients obtained acceptable level of vitamin D sufficiency (≥30 ng/ml). After 
3 months of the treatment, Group 1 patients showed a significant decrease in mean SOD3 level compared to pre-treatment level (p<0.05), while 
Group 2 patients showed a significant increase in mean SOD3 level compared to pre-treatment level (p<0.05).
Conclusion: Most of the asthmatic patients revealed vitamin D deficiency and supplementation with vitamin D3 reduce oxidative stress burden in 
those patients.
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INTRODUCTION
Asthma is a chronic inflammatory disorder of the airways, and this 
inflammation causes recurrent episodes of wheezing, chest tightness, 
breathlessness, and coughing, especially at night or early morning [1]. 
There is an increased oxidative stress in asthma caused by inflammatory 
cells, such as macrophages and eosinophils which produce reactive 
oxygen species (ROS) [2]. Increased oxidative stress in asthma is 
confirmed by the increased concentrations of 8-isoprostane (which is 
a product of oxidized arachidonic acid) and ethane (which is a product 
of lipid peroxidation) in the exhaled air of asthmatic patients [3,4]. 
Oxidative stress increment is associated with disease severity, 
exaggerate the inflammatory response, and decrease responsiveness 
to corticosteroids [2]. Many cells of the respiratory tract, including 
macrophages and epithelial cells, produce antioxidants enzymes such 
as superoxide dismutase (SOD), and catalase [5].
Oxidative stress results from excessive exposure to reactive oxygen and 
nitrogen species due to inflammation or environmental air pollution and 
cigarette smoke which leads to damage of proteins, lipids, and DNA [6]. 
The rapid reaction of nitric oxide with ROS and the specific localization 
of antioxidant enzymes, such as superoxide in the lung suggest that 
antioxidant enzymes might also function as cell signaling agents or 
regulators of cell signaling [6]. ROS could exacerbate asthma via effects 
on airway smooth muscle and mucin secretion. The first effect, ROS 
decrease β-adrenergic function in lungs, and sensitize airway muscles 
to acetylcholine inducing contraction, activates mitogen-activated 
kinases in tracheal myocytes and stimulates tracheal smooth muscle 
contraction [6]. The second effect, ROS have been reported to stimulate 
mucin secretion [7].
The primary defense against ROS is endogenous antioxidants, 
which include the families of SOD, catalase, glutathione peroxidase, 
glutathione S-transferase, and thioredoxin with their subtypes, for 
example, the three mammalian SOD are cytosolic (SOD1, copper-zinc 
SOD), mitochondrial (SOD2, manganese SOD), and extracellular SOD 
(EC-SOD, SOD3), and two thioredoxins; the cytosolic (Trx1) and the 
mitochondrial (Trx2) one [6,8]. SOD activity is reduced in the asthmatic 
airway [9], mainly during exacerbation with enhanced production of 
oxygen radicals by inflammatory cells [10], where its activity in the lung 
is related to airway hyperreactivity and airflow limitation [9]. EC-SOD, 
SOD3 is the primary EC-SOD enzyme and is highly expressed in human 
lungs approximately 8 times that of the liver, 6 times that of the brain, 
2-3 times that of the heart, and 1-2 times that of the kidney [11].
Many studies point out that SOD activity might play a role in asthma. First, a 
study showed that there was a reduction of airway hyperresponsiveness in 
rabbits after intravenous administration of polyethylene glycol conjugated 
SOD suggest that increased SOD activity may attenuate asthma [12]. The 
second one, after antigen challenge, airway macrophages from individuals 
with asthma produce more superoxide anion than control subjects [13]. 
Third, a study showed that SOD activity is decreased in asthmatic patients 
cells of bronchoalveolar lavage and brushings [14]. Another study showed 
that asthmatic patients who are responsive and controlled with inhaled 
corticosteroids and long-acting β2-agonists had higher lipid peroxide 
levels when compared with healthy controls [15].
Vitamin D is an essential nutrient that is usually obtained through 
exposure to sunlight, and secondarily through diet and dietary 
supplements [16].
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Many studies identified the complex role of vitamin D in immune 
responses regulation. Various immune cell types express VDRs, 
including activated T-lymphocyte, β-cells, macrophages, and dendritic 
cells [16,17]. Expression of 1α-hydroxylase (the enzyme responsible for 
the production of active form of vitamin D) by cells at extra-renal sites 
improve both the capacity for extra-renal synthesis of the active form 
of vitamin D and to modulate innate and adaptive immune function at 
these sites [16].
This study was designed to evaluate the potential antioxidant effect of 




This is a prospective randomized-controlled open-label interventional 
study to evaluate the antioxidant effect of vitamin D3 in asthma 
patients.
Patients
A total of 44 candidate patients were diagnosed with asthma during 
their visit to hospital. The patients were under the supervision of 
pulmonary specialist and were treated according to clinical practice 
guideline and disease severity.
The Local Clinical Research Ethics Committee, in accordance with 
Helsinki Declaration 1998, approved the study protocol and all subjects 
gave written informed consent to participate in the study. The eligible 
patients and subjects were allocated into three main groups:
• Group 1: Include 20 patients who have diagnosed with asthma are 
assigned to receive conventional therapy for asthma according to 
disease stage and severity for 3-month period
• Group 2: Include 24 patients who have diagnosed with asthma are 
assigned to receive conventional therapy for asthma according to 
disease stage and severity plus 2000 IU vitamin D3 fast dissolve mini 
tablet (Natrol, USA) for 3-month period
• Control group: Include 30 apparently healthy control subjects.
Pulmonary function test (PFT) using spirometry
It was measured using Spiro Air (volumetric PFT) (Medisoft, Belgium) in 
which forced expiratory volume in 1 second (FEV1) both the measured 
and percentage of predicted value in addition to FEV1/forced vital 
capacity (FEV1/FVC) ratio were measured before and after 3 months 
therapy for both Groups 1 and 2 patients.
Specimens collection
To 5 ml of venous blood were drawn using a plastic disposable syringe 
and collected in disposable plain tube (gel and clot activator) and was 
allowed to clot and separated by centrifuge at speed of 3000 rpm for 
10 minutes. The serum samples were stored at −40°C until the time of 
examination.
Serum 25-hydroxy (25[OH]) vitamin D level measurement
It was determined using commercial enzyme-linked immunosorbent 
assay (ELISA) kit (Euroimmun, Germany), measured at baseline in 
Group 1, Group 2 patients and healthy control group and after 3 months 
treatment in Groups 1 and 2 patients. 
Serum EC-SOD, SOD3
It was determined using commercial ELISA kit (Elabscience 
Biotechnology, China) measured before and after 3 months therapy for 
both Groups 1 and 2 patients.
Statistical analysis
The Statistical Analysis System Minitab 16.1 (2010) was used. Data 
presented as mean±standard deviation. Pearson Chi-square test was 
utilized to detect significant differences among demographic variables, 
while paired t-test was used to compare between pre- and post-
treatment results; two-sample t-test was used to compare pre- or post-
treatment between Groups 1 and 2. Analysis of variance was utilized 
to compare between the studied parameters among different patient 
groups.
NS: No significant differences (p>0.05), *significant difference (p<0.05), 
**highly significant difference (p<0.01).
RESULTS
Patients demographic and disease characteristics
The patient demographic and disease characteristic for 74 subjects 
including 53 female (71.6%) and 21 male gender (28.4%) with no 
significant statistical difference was found among study groups in respect 
to both genders (p>0.05) (Table 1). The age range for the groups where 
between 14 and 71 years with the mean age of the study groups was 
as follows: Group 1 patients (40.75±17.31) years, and Group 2 patients 
(41.4±13.6) years, and control group (45.86±15.83) years with no 
statistically significant difference was found among study groups with 
respect to age (p>0.05). Positive family history of asthma was found in 
65% and 58.3% of Groups 1 and 2 patients, respectively, while negative 
family history was found in 35% and 41.7% for Groups 1 and 2 patients, 
respectively, with no statistically significant difference between these 
groups (p>0.05). Considering the patients residence there were 85% 
of Group 1 patients versus 79.2% of Group 2 patients were urban, and 
15% of Group 1 patients versus 20.8% of Group 2 patients were rural 
with no significant statistical difference between both groups (p>0.05). 
The duration of the disease for Groups 1 and 2 patients, respectively, 
were as follows: 80% versus 62.5% for <20 years, 15% versus 25% for 
21-40 years duration, 5% versus 12.5% for 41-60 years duration, with 
a mean of 12.8±11.2 years for Group 1 patients and 20.2±15.4 years for 
Group 2 patients, respectively, and no statistically significant difference 
was found between both groups in respect to duration of the disease 
(p>0.05).
Effect of conventional therapy alone and in combination with 
vitamin D3 supplement on PFT using spirometry in asthmatic 
patients
The mean FEV1 both the measured and the percentage of predicted 
value showed no significant difference at baseline and after 3 months 
between the study groups (1 and 2) (p>0.05) while highly significant 
increase was noticed after 3 months treatment compared to pre-
treatment value for both Groups 1 and 2 patients (p<0.01). The 
mean FEV1/FVC ratio showed a significant difference at baseline 
level between Groups 1 and 2 (p<0.05), but no significant differences 
was found after 3 months between both groups (p>0.05). There 
was no significant increase in (FEV1/FVC) ratio after 3 months 
in Group 1 when compared to pre-treatment value (p>0.05), 
nevertheless, Group 2 showed highly significant increase after 
3 months treatment compared to pre-treatment value (p<0.01) 
(Table 2).
Effect of conventional therapy alone and in combination with 
vitamin D3 supplement on endogenous vitamin D status in 
asthmatic patients treated for 3 months compared with healthy 
control group
The endogenous vitamin D status at a baseline in 18 patients in Group 1, 
23 patients in Group 2, 24 subjects in control group were considered 
as vitamin D deficiency (<20 ng/ml) with a statistically significant 
differences were seen among study groups (p<0.05). On the other 
hand, 2 patients in Group 1, 1 patient in Group 2, 4 subjects in control 
group had vitamin D insufficiency (20-29 ng/ml) with no statistically 
significant differences were found among study groups (p>0.05). Only 
2 subjects in control group were found to have a vitamin D sufficiency 
(≥30 ng/ml) (Table 3). After 3 months, the endogenous vitamin D status 
showed deficiency (<20 ng/ml) in 15 patient of Group 1 and 8 patient 
of Group 2 with highly significant differences between both groups 
(p<0.01). Vitamin D insufficiency (20-29 ng/ml) was found in 5 patients 
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of Group 1 and 10 patients of Group 2 with no significant differences 
between both Group 1 and Group 2 (p>0.05). Only 6 patients of Group 2 
found to have vitamin D sufficiency (≥30 ng/ml) after 3 months 
treatment.
Effect of conventional therapy alone and in combination with 
vitamin D3 supplement on EC-SOD, SOD3 level in asthmatic patients
There was a highly significant differences in the mean SOD3 levels 
at baseline between both Groups 1 and 2 patients (p<0.01), and 
no significant differences was seen post-treatment between both 
study groups (p>0.05) (Table 4). After 3 months of the treatment, 
Group 1 patients showed a significant decrease in mean SOD3 
level compared to pre-treatment level (p<0.05). On the other hand, 
Group 2 patients showed a significant increase in mean SOD3 level 
compared to pre-treatment level (p<0.05).
DISCUSSION
Asthma is one of the most common chronic diseases and considered a 
major public health problem worldwide [18], and the exact mechanism 
of vitamin D in oxidative stress and asthma exacerbation remains 
unclear [19]. Vitamin D might play either preventive or protective role 
against the development of asthma, effective to be a good candidate as 
an adjuvant therapy [20].
With reference to the results in this study, highly significant increase in 
both measured and percentage of predicted value of FEV1 in both study 
groups after 3 months treatment when compared to pre-treatment 
value suggesting that this improvement was due to conventional 
therapy rather the effect of vitamin D3 supplementation. On the other 
hand, highly significant increase in the ratio of FEV1/FVC in Group 2 
after 3 months treatment with vitamin D3 supplementation when 
compared to Group 1 (p<0.01).
The FEV1 is generally considered as efficacy parameters in asthma 
clinical trials in which patient education increased the FEV1 values 
in the asthmatic patients due to a better practice followed in using 
the medications [21]. Tamašauskienė et al. showed no correlations 
between vitamin D levels and lung function (FEV1, FEV1/FVC) while 
an inverse positive correlation was noticed between vitamin D level 
and FEV1/FVC in asthmatic smokers [22]. Columbo et al. found no 
significant association between serum vitamin D and spirometric 
values even in subjects with lower FEV1% (<70%) and after 12 weeks 
treatment with 2000 IU vitamin D3 supplementation [23]. In addition, 
Nageswari et al. investigated the addition of 1000 IU of vitamin D3 
to conventional therapy when compared to conventional therapy 
alone on PFT; he found that patients in both groups had a significant 
Table 1: Patients demographic and disease characteristics
Variables Study groups
Group 1 Group 2 Control group p value
Age (year) 40.75±17.31aNS 41.4±13.6aNS 45.86±15.83 0.890bNS
Gender N (%) N (%) N (%)
Female 13 (65.0) 20 (83.3) 20 (66.7) 0.299NS
Male 7 (35.0) 4 (16.7) 10 (33.3)
Total 20 (100) 24 (100) 30 (100)
Family history
Positive 13 (65.0) 14 (58.3) -
Negative 7 (35.0) 10 (41.7) - 0.651NS
Residence
Urban 17 (85.0) 19 (79.2) - 0.617NS
Rural 3 (15.0) 5 (20.8) -
Duration of the disease (year)
≤20 16 (80.0) 15 (62.5) - 0.072NS
21-40 3 (15.0) 6 (25.0) -
41-60 1 (5.0) 3 (12.5) -
≥61 None None -
Data presented as mean±SD. aComparison with control group. bComparison between Group 1 and 2. NS: No significant differences (p>0.05). SD: Standard deviation
Table 2: Effect of conventional therapy alone and in combination 
with vitamin D3 supplement on PFT using spirometry in 
asthmatic patients treated for 3 months
Variables Study groups
Group 1 Group 2 p value
FEV1(L) Meas.
Pre-treatment 1.584±0.871 1.189±0.514 0.084NS
Post-treatment 2.091±1.013 1.753±0.674 0.212NS
p value 0.009** 0.000** -
FEV1 (% Pred.Val.)
Pre-treatment 50.90±16.04 43.92±20.36 0.210NS
Post-treatment 68.85±14.93 63.04±20.68 0.287NS
p value 0.003** 0.000** -
FEV1/FVC (%)
Pre-treatment 74.37±13.25 63.62±14.33 0.013*
Post-treatment 78.30±12.58 71.45±13.15 0.086NS
p value 0.341NS 0.005** -
Data presented as mean±SD, FEV1(L): Forced expiratory volume in 1 second 
in liter, FEV1/FVC: Forced expiratory volume in one second/forced vital 
capacity ratio, % Pred.Val.: Percentage of predicted value, Meas.: Measured 
value. NS: No significant differences (p>0.05), *significant difference (p<0.05), 
**highly significant difference (p<0.01). PFT: Pulmonary function test, 
SD: Standard deviation
Table 3: Effect of conventional therapy alone and in combination 
with vitamin D3 supplement on endogenous vitamin D status in 
asthmatic patients treated for 3 months compared with healthy 
control group
Variables Study groups
Group 1 Group 2 Control 
group
p value
Endogenous vitamin D level (ng/ml)
Pre-treatment
Deficiency (<20) 18 (90) 23 (96) 24 (80) 0.015*
Insufficiency (20-29) 2 (10) 1 (4) 4 (13) 0.623NS
Sufficiency (≥30) 0 (0) 0 (0) 2 (7) -
Total 20 (100) 24 (100) 30 (100) -
Post-treatment
Deficiency (<20) 15 (75) 8 (33) - 0.009**
Insufficiency (20-29) 5 (25) 10 (42) - 0.472NS
Sufficiency (≥30) 0 (0) 6 (25) - -
Total 20 (100) 24 (100) - -
Data presented as N (%), endogenous vitamin D measured as (25-OH 
vitamin D). NS: No significant differences (p>0.05), *significant 
difference (p<0.05), **highly significant difference (p<0.01). 25-OH: 25-hydroxy
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improvement in percentage of predicted value of FEV1 after 3 months 
treatment [24].
Many other studies correlate vitamin D status to PFT. Recent 
study published in China showed that patients with severe asthma 
exacerbation and vitamin D deficiency had lower FEV1% and decreased 
corticosteroid response when compared to vitamin D sufficient 
asthmatic patients [19]. Another study in asthmatic patients the serum 
25(OH) vitamin D was positively correlated with FEV1% predicted and 
FEV1/FVC ratio [25].
This study showed that at baseline, 90% of Group 1, 96% of Group 2, 
and 80% of the control group had vitamin D deficiency (<20 ng/ml). 
Furthermore, 10% of Group 1, 4% of Group 2, and 13% control group 
had vitamin D insufficiency (20-29 ng/ml). Only 7% of the control 
group had vitamin D sufficiency (≥30 ng/ml). A similar finding had 
been stated by many studies with the same result on elderly asthmatic 
patients, where (79%) had lower than normal serum vitamin D at 
baseline [23]. These results confirm that vitamin D deficiency and 
insufficiency are extremely common in patients with asthma [26], 
and mostly pronounced in patients with severe and/or uncontrolled 
asthma [18]. Kamran et al. found a high prevalence of vitamin D 
deficiency and insufficiency (88.10%) in adult patients with moderate 
to severe persistent asthma [27]. Furthermore, Freishtat et al. found 
a high prevalence of vitamin D deficiency and insufficiency among 
African-American youth with asthma in Washington, DC [28]. Moreover, 
another study explained the association between vitamin D level 
and respiratory outcome in Canadian adult, in this study vitamin D 
deficiency might be associated with increased risk of current and ever 
asthma [29].
The severity of asthma control might be correlated with lifestyle and 
dietary changes as a reverse causal effect (i.e., severe asthma leading to 
vitamin D insufficiency), which may be attributed to a less time spent 
outdoors, limited activity, and medication. Another causal effect is that 
asthma severity is negatively influenced by vitamin D insufficiency that 
occurred independently of asthma morbidity or control [26]. One study 
suggested that the daily oral intake of vitamin D in sunlight deprived 
individuals should exceed 600 IU; most probably it should be 1000 IU 
day to secure a normal level of 25(OH) vitamin D [30].
Recent study found that vitamin D reduce inflammatory burden 
in asthmatic patient [31], while other studies have demonstrated 
alterations in different endogenous antioxidants in patients with 
asthma which may involve either an increase or a decrease pattern 
depending on the changes occurring due to a defense response [32]. 
In this study, the effect of vitamin D3 supplementation on EC-SOD, 
SOD3 showed a significant increase in SOD3 antioxidant enzyme after 
3 months treatment with vitamin D3 supplementation to conventional 
therapy in Group 2 patients (p<0.05), meanwhile significant decrease 
of this enzyme activity after 3 months treatment with conventional 
therapy alone in Group 1 patients (p<0.05). These result highlighted 
a potential effect of vitamin D3 in activating this antioxidant enzyme. 
Highly significant differences in SOD3 level were detected at baseline 
between asthmatic groups which can be explained by the difference in 
the severity of the disease at which the patients presented with along 
with the fact that conventional therapy might failed to control the 
oxidative level at different steps of treatment.
This study was designed to examine the SOD3 activity in serum for a 
number of reason; first, blood is considered as an important pool of 
antioxidant defenses in the body. Second, asthma is an inflammatory 
disease in which cells are recruited from the peripheral blood into the 
airways. Third, blood is an easily available source to study the oxidant-
antioxidant imbalance rather than bronchoalveolar fluid which is 
obtained through an invasive bronchoscope technique which only be 
performed in patients with stable asthma and who are likely to show 
less marked alterations in the oxidant-antioxidant balance observed in 
a more unstable state [32,33].
Loss of serum SOD activity in asthma may thus reflect a greater 
magnitude and/or ongoing systemic oxidative stress in patients with 
asthma with severe airflow limitation, with a consequent greater 
oxidative modification of SOD systemically in addition to allergen-
triggered inflammatory pathways may participate in loss of systemic 
SOD activity, perhaps through increasing oxidative stress [6,34,35], 
and subsequent inactivation of SOD [8]. Lan et al. found that SOD in 
vitamin D deficient patients was significantly decreased compared to 
SOD in vitamin D sufficient patients in severe asthma exacerbation 
indicated that vitamin D deficiency aggravated the oxidative changes, 
increased oxidative stress, and DNA damage in severe asthma 
exacerbation [19], also the ROS levels were significantly decreased in 
the vitamin D deficient patients treated with methylprednisolone and 
vitamin D3 compared to that in the vitamin D sufficiency patients treated 
with methylprednisolone alone [19]. Previous studies showed that SOD 
activity was lower in asthmatic patients as compared with control, and 
activity loss was significantly related to airflow limitation suggest that 
the lower SOD activity in asthma may derive from airway inflammation 
and injury, cell turnover, and release of inactive SOD [5,8,32,36].
CONCLUSION
This study revealed that vitamin D reduce oxidative stress burden in 
asthmatic patients, suggesting that vitamin D plays effective role to be 
a good candidate as an adjuvant therapy. Further evaluation is needed 
to explore the potential effect of vitamin D supplementation in acute or 
chronic asthma using different oxidative markers at different stages of 
disease severity.
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